ClinicalTrials.gg

Program

afimkibart

Also written as “Afimkibart”, “PF-06480605” and “RO7790121”.

Its studies are mostly in Colitis, Ulcerative · Crohn Disease · Dermatitis, Atopic · Arthritis, Rheumatoid, led by Hoffmann-La Roche.

Furthest: phase 3, since Sep 6, 202418 company-led studies, 14 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche1814 open or runningphase 3since Sep 6, 2024Nov 14, 2013Dec 31, 2026phase 2 · NCT05910528
  • Named in Hoffmann-La Roche’s own pipeline as RG6631 afimkibart, phase 3, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Pfizer.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Nov 14, 2013.

  1. Sep 12, 2019Phase 2 study in Moderate to Severe Ulcerative ColitisNCT04090411 · 246 enrolled · United States, Australia, Belgium and more
  2. Jan 22, 2020Phase 1 study in HealthyNCT04269538 · 16 enrolled · Japan
  3. Jun 9, 2023Phase 2 study in Crohn DiseaseNCT05910528 · 21 enrolled · United States, Belgium, France and more
  4. Sep 6, 20242 phase 3 studies in Moderately to Severely Active Ulcerative ColitisNCT06589986, NCT06588855
  5. Feb 6, 20252 phase 3 studies in Moderately to Severely Active Crohns DiseaseNCT06819891, NCT06819878
  6. Mar 4, 2025Phase 2 study in Dermatitis, AtopicNCT06863961 · 162 enrolled · United States, Brazil, Canada and more
  7. Mar 18, 2025Phase 1 study in MASHNCT06903065 · 56 enrolled · United States, Mexico, Puerto Rico
  8. Aug 15, 2025Phase 2 study in Arthritis, RheumatoidNCT07137598 · 160 planned · United States, Argentina, Belgium and more
  9. Aug 28, 2025Phase 3 study in Moderately to Severely Active Ulcerative ColitisNCT07158242 · 100 planned · United States, Australia, Brazil and more
  10. Oct 30, 2025Phase 2 study in Dermatitis, AtopicNCT07223697 · 120 enrolled · United States, Brazil, Canada and more
  11. Dec 19, 2025Phase 3 study in Moderately to Severely Active Crohns DiseaseNCT07298421 · 100 planned · United States, Australia, Brazil and more
  12. May 27, 2026Phase 2 study in Arthritis, RheumatoidNCT07620392 · 120 planned · United States, Brazil, Poland
  13. Jun 19, 2026Phase 1 study in Active Ulcerative ColitisNCT07665723 · 25 planned · United States, Belgium, Germany and more
  14. Sep 10, 2026Phase 3 study in Moderately to Severely Active Ulcerative ColitisNCT07846683 · 350 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Crohn DiseaseNCT05910528
  2. Jan 30, 2027Primary completion: phase 3 study in Moderately to Severely Active Ulcerative ColitisNCT06589986
  3. Apr 17, 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07137598
  4. Jul 31, 2027Primary completion: phase 1 study in Active Ulcerative ColitisNCT07665723

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07846683Moderately to Severely Active Ulcerative Colitis · United States3RecruitingMay 31, 2028350
NCT07665723Active Ulcerative Colitis · United States, Belgium, Germany and more1RecruitingJul 31, 202725
NCT07620392Arthritis, Rheumatoid · United States, Brazil, Poland2RecruitingJul 8, 2033120
NCT07298421Moderately to Severely Active Crohns Disease · United States, Australia, Brazil and more3RecruitingMay 31, 2030100
NCT07223697Dermatitis, Atopic · United States, Brazil, Canada and more2Active, not recruitingMar 1, 2033120
NCT07158242Moderately to Severely Active Ulcerative Colitis · United States, Australia, Brazil and more3RecruitingMar 31, 2030100
NCT07137598Arthritis, Rheumatoid · United States, Argentina, Belgium and more2RecruitingApr 17, 2027160
NCT06903065MASH · United States, Mexico, Puerto Rico1Active, not recruitingSep 24, 202656
NCT06863961Dermatitis, Atopic · United States, Brazil, Canada and more2Active, not recruitingJul 22, 2026162
NCT06819891Moderately to Severely Active Crohns Disease · United States, Argentina, Australia and more3RecruitingDec 31, 2028425
NCT06819878Moderately to Severely Active Crohns Disease · United States, Argentina, Australia and more3RecruitingDec 31, 2028600
NCT06589986Moderately to Severely Active Ulcerative Colitis · United States, Argentina, Australia and more3Active, not recruitingJan 30, 2027400
NCT06588855Moderately to Severely Active Ulcerative Colitis · United States, Argentina, Australia and more3Active, not recruitingOct 29, 2026350
NCT05910528Crohn Disease · United States, Belgium, France and more2Active, not recruitingDec 31, 202621
NCT04269538Healthy · Japan1CompletedNov 11, 202016
NCT04090411Moderate to Severe Ulcerative Colitis · United States, Australia, Belgium and more2CompletedOct 25, 2022246
NCT02840721Colitis, Ulcerative · United States, Belgium, Italy and more2CompletedMay 31, 201850
NCT01989143Healthy · United States1CompletedMar 201592

How it is read

Names in the registry

  • “Afimkibart”, 13 entries
  • “PF-06480605”, 5 entries
  • “RO7790121”, 1 entry
  • “Induction- PF-06480605 150 mg SC Q4W”, 1 entry
  • “Induction- PF-06480605 450 mg SC Q4W”, 1 entry

Codes read as this program: PF06480605.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.